David Pulido

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.

Journal: The Lancet. Infectious diseases

Published: March 25, 2024

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.

Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex.

Journal: Nature communications

Published: February 20, 2024

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies.

Journal: Cell reports. Medicine

Published: January 05, 2024

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting.

Journal: Frontiers in cellular and infection microbiology

Published: September 20, 2022

Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.

Streptococcus pneumoniae colonization associates with impaired adaptive immune responses against SARS-CoV-2.

Journal: The Journal of clinical investigation

Published: November 30, 2021

Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.

Heterotypic interactions drive antibody synergy against a malaria vaccine candidate.

Journal: Nature communications

Published: November 11, 2021

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.

Journal: EBioMedicine

Published: September 07, 2021

Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.

Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein.

Journal: mSphere

Published: August 11, 2021

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination.

Journal: Med (New York, N.Y.)

Published: July 05, 2021

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.

Journal: bioRxiv : the preprint server for biology

Published: January 27, 2021

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.

Journal: ACS central science

Published: January 18, 2021

Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.

Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies.

Journal: Cell reports. Medicine

Published: January 11, 2021

Showing 1-12 of 38

Last Updated: 09/26/2026